Pluronic F-127 | 721929-01-7

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: Pluronic F-127
• 英文别名: 2-[2-(2-hydroxyethoxy)propoxy]ethanol
• CAS: 721929-01-7
• 化学式: C₇H₁₆O₄
• 分子量: 164.2
• InChiKey: OQNWUUGFAWNUME-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1
• 重原子数：
  11
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  58.9
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• THERAPEUTIC COMPOUNDS AND USES THEREOF
  申请人：Kala Pharmaceuticals, Inc.

  公开号：US20140235634A1

  公开（公告）日：2014-08-21

  Described herein are compounds of Formula (I) or Formula (VI), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Also provided are particles (e.g., nanoparticles) comprising compounds of Formula (I) or Formula (VI) and pharmaceutical compositions thereof that are mucus penetrating. Methods of using the compounds or pharmaceutical compositions thereof for treating diseases are also provided.

  本文描述了公式（I）或公式（VI）的化合物，其药学上可接受的盐以及其药物组合物。还提供了包含公式（I）或公式（VI）化合物及其药物组合物的微粒（例如，纳米颗粒），这些微粒具有穿透黏液的特性。还提供了使用这些化合物或药物组合物治疗疾病的方法。
• [EN] POLY(KETALS) AND RELATED COMPOSITIONS AND METHODS<br/>[FR] POLYCÉTALS ET COMPOSITIONS ET PROCÉDÉS ASSOCIÉS
  申请人：CHILDREN'S MEDICAL CENTER CORP

  公开号：WO2017189953A1

  公开（公告）日：2017-11-02

  Compositions comprising polymers comprising one or more ketal, monothioketal, and/or thioketal bonds are provided, as well as related methods and kits. In some embodiments, a polymer may comprise one or more repeat units comprising one or more ketal, monothioketal, and/or thioketal bonds and a precursor of a pharmaceutically active agent. The precursor of the pharmaceutically active agent may be located in the backbone or may be a pendant group. The polymer may degrade in certain environments (e.g., aqueous environments, acidic environments, in vivo, etc.) to produce the pharmaceutically active agent and other biocompatible degradation products, such as certain ketones, alcohols, and/or thiols. Regardless of the location of the precursor of the pharmaceutically active agent in the repeat unit(s), the polymer may have a prolonged degradation time and/or release of the pharmaceutically active agent in certain environments. Various compositions, described herein, may be particularly well suited for applications requiring extended release of pharmaceutically active agents, such as the treatment of ophthalmic disorders.

  提供了包含聚合物的组合物，其中聚合物包含一个或多个缩醛基、单硫缩醛基和/或硫缩醛基的键，以及相关方法和试剂盒。在某些实施例中，聚合物可以包含一个或多个重复单元，其中包含一个或多个缩醛基、单硫缩醛基和/或硫缩醛基的键以及药用活性剂的前体。药用活性剂的前体可以位于骨架中或可以是一个挂链基团。聚合物可以在某些环境中降解（例如水性环境、酸性环境、体内等），以产生药用活性剂和其他生物相容性降解产物，例如某些酮类、醇类和/或硫醇。无论药用活性剂的前体在重复单元中的位置如何，聚合物在某些环境中可能具有较长的降解时间和/或释放药用活性剂。本文描述的各种组合物可能特别适用于需要延长释放药用活性剂的应用，例如治疗眼科疾病。
• COMPOSITION OF A 5-HT2A SEROTONIN RECEPTOR MODULATOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO
  申请人：Arena Pharmaceuticals

  公开号：US20160067216A1

  公开（公告）日：2016-03-10

  The present invention relates to certain compositions of a 5 -HT 2A serotonin receptor modulator and methods for their preparation. The compositions disclosed herein are useful for increasing slow wave sleep, improvise sleep consolidation, improving sleep maintenance and improving sleep quality, and for treating insomnia and related sleep disorders, dyssomnias, parasomnias and nonrestorative sleep and the like. The compositions disclosed herein are further useful for treating platelet aggregation, coronary artery disease, myocardial, infarction, transient ischemic attack, angina, stroke, atrial fibrillation, thrombosis, asthma or symptoms thereof, agitation or symptoms thereof, behavioral disorders, drug induced psychosis, excitative psychosis, Gilles de la Tourette's syndrome, manic disorder, organic or NOS psychosis, psychotic disorders, psychosis, acute schizophrenia, chronic schizophrenia, NOS schizophrenia and related disorders, diabetic-related disorders and progressive multifocal leukoencephalopathy and the like.

  本发明涉及某些5-HT2A 5-羟色胺受体调节剂的组合物及其制备方法。本文所披露的组合物有助于增加慢波睡眠、改善睡眠巩固、改善睡眠维持和改善睡眠质量，用于治疗失眠和相关的睡眠障碍、睡眠节律紊乱、睡眠中的异常行为和非恢复性睡眠等。本文所披露的组合物还有助于治疗血小板聚集、冠状动脉疾病、心肌梗塞、短暂性脑缺血发作、心绞痛、中风、房颤、血栓形成、哮喘或其症状、激动或其症状、行为障碍、药物诱导的精神病、兴奋性精神病、Gilles de la Tourette综合征、躁狂障碍、器质性或NOS精神病、精神病性障碍、精神病、急性精神分裂症、慢性精神分裂症、NOS精神分裂症和相关疾病、糖尿病相关疾病和进行性多发性白质脑病等。
• ANTIPARASITIC ISOXAZOLINE COMPOUNDS, LONG-ACTING INJECTABLE FORMULATIONS COMPRISING THEM, METHODS AND USES THEREOF
  申请人：MERIAL INC.

  公开号：US20170239218A1

  公开（公告）日：2017-08-24

  This invention relates to long-acting injectable compositions for combating parasites in animals, comprising at least one isoxazoline active agent, a liquid PEG and/or a neutral oil, optionally a co-solvent, and optionally a pharmaceutically acceptable additive or excipient. This invention also provides new isoxazoline active agents with long-lasting efficacy against ectoparasites. The invention also provides for improved methods for eradicating, controlling, and preventing parasite infections and infestations in an animal comprising administering the novel isoxazoline compounds and long-acting injectable compositions of the invention to the animal in need thereof.

  该发明涉及一种用于对抗动物寄生虫的长效注射剂组合物，包括至少一种异唑啉类活性剂、液态PEG和/或中性油、可选的共溶剂以及可选的药用添加剂或赋形剂。该发明还提供了新的异唑啉类活性剂，具有长效抗外寄生虫的功效。该发明还提供了改进的方法，用于根除、控制和预防动物寄生虫感染和寄生，包括向需要该组合物的动物注射该发明的新异唑啉类化合物和长效注射剂组合物。
• CONTROLLED RELEASE ANTIMICROBIAL COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC DISORDERS
  申请人：LICHTER Jay

  公开号：US20100036000A1

  公开（公告）日：2010-02-11

  Disclosed herein are compositions and methods for the treatment of otic diseases or conditions with antimicrobial agent compositions and formulations administered locally to an individual afflicted with an otic disease or condition, through direct application of these compositions and formulations onto or via perfusion into the targeted auris structure(s).

  本文公开了用抗微生物药物组合物和制剂治疗耳疾或病症的组合物和方法，通过将这些组合物和制剂直接应用于或通过灌注进入目标耳结构，局部治疗患有耳疾或病症的个体。